<DOC>
	<DOCNO>NCT01243242</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability metadoxine ( MG01CI ) extend release formulation treatment adult diagnose ADHD</brief_summary>
	<brief_title>Clinical Efficacy &amp; Safety , Metadoxine ( MG01CI ) Extended Release Attention-Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group , multicenter study adult subject ADHD . Eligible subject randomly assign 1:1 ratio one two treatment group , 1400 mg Metadoxine ( MG01CI ) Placebo . The study consist three period : screening period 2 week , 6-week double-blind treatment period , 2-week safety follow-up period . The total duration subject participation ~10 week . Overview Study Visits Screening Period : Visit 1 - Screening/Baseline Visit ( 14 day prior dose ) Treatment Period : Visit 2 - Day 0 ( Randomization Visit ) Visit 3 - Day 7 ± 2 day Visit 4 - Day 14 ± 2 day Visit 5 - Day 28 ± 2 day Visit 6 - Day 42 ± 2 day Follow-up period : Visit 7 - Day 56 ± 3 day</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>1 . Adult male female , 18 50 year old , inclusive , screen visit 2 . Diagnosed ADHD base 1 . DSMIV criterion ADHD assess Adult ADHD Clinician Diagnostic Scale ( ACDS V1.2 ) 2 . SCID clinical interview 3 . Clinical severity least moderate level ( Clinical Global Impression score 4 ) 4 . Female subject childbearing potential must agree use effective contraceptive negative urine pregnancy test screen visit 5 . Able attend clinic regularly reliably 6 . Able swallow tablets/capsules 7 . Able understand , read , write speak Hebrew fluently complete study relate material 8 . Able understand sign write informed consent participate study 1 . Subjects nonresponder least two ADHD treatment 2 . Subjects medical psychiatric condition ( e.g . schizophrenia , personality disorder diagnose DSMIV ) clinical significant unstable medical surgical condition may preclude safe complete study participation determine medical history , physical examination , neurological exam , laboratory test ECG base opinion Investigator ; common disease hypertension , type 2 diabetes mellitus , hyperlipidemia , etc . allow per Investigator 's judgment , long stable control medical therapy constant least 8 week prior randomization throughout study 3 . Any prescription nonprescription ADHD medication 7 day prior screen visit 4 . Known suspected HIVpositive advance disease AIDS , Hepatitis C , Hepatitis B tuberculosis 5 . History allergy sensitivity B complex vitamins 6 . History suspicion PDD , NLD psychotic condition 7 . Use Vitamin B throughout study 8 . Use ADHD medication throughout study 9 . Use psychiatric medication throughout study 10 . Use investigational medication/treatment past 30 day prior screen visit per discretion Investigator 11 . Use medication food supplement consider acceptable clinical Investigator medical monitor 14day period randomization 12 . Current ( history within last 6 month ) drug dependence substance abuse disorder accord DSMIVTR criterion ( exclude nicotine ) . Subjects also agree refrain consume abnormally high amount caffeine study . 13 . Suicidality , define either active suicidal plan/intent active suicidal thought , 6 month Screening Visit lifetime suicide attempt . 14 . Blind subject 15 . Any relation Sponsor , Investigator study staff 16 . Any condition , opinion Principal Investigator would place subject risk influence conduct study interpretation result , include ( limited ) abnormally low intellectual capacity . 17 . Subjects fully comprehend implication protocol comply requirement capable follow study schedule reason 18 . Pregnancy , lactation inadequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ADHD , Adults , MG01CI , METADOXINE</keyword>
</DOC>